Jodi M Gilman1, Vanessa Calderon2, Max T Curran2, A Eden Evins2. 1. Center for Addiction Medicine, Massachusetts General Hospital, Department of Psychiatry, Harvard Medical School, USA. Electronic address: jgilman1@partners.org. 2. Center for Addiction Medicine, Massachusetts General Hospital, Department of Psychiatry, Harvard Medical School, USA.
Abstract
BACKGROUND: Though substance use is often associated with elevated risk-taking in real-world scenarios, many risk-taking tasks in experimental psychology using financial gambles fail to find significant differences between individuals with substance use disorders and healthy controls. We assessed whether participants using marijuana would show a greater propensity for risk-taking in distinct domains including, but not limited to, financial risk-taking. METHODS: In the current study, we assessed risk-taking in young adult (age 18-25) regular marijuana users and in non-using control participants using a domain-specific risk-taking self-report scale (DOSPERT) encompassing five domains of risk-taking (social, financial, recreational, health/safety, and ethical). We also measured behavioral risk-taking using a laboratory monetary risk-taking task. RESULTS: Marijuana users and controls reported significant differences on the social, health/safety, and ethical risk-taking scales, but no differences in the propensity to take recreational or financial risks. Complementing the self-report finding, there were no differences between marijuana users and controls in their performance on the laboratory risk-taking task. CONCLUSIONS: These findings suggest that financial risk-taking may be less sensitive than other domains of risk-taking in assessing differences in risky behavior between those who use marijuana and those who do not. In order to more consistently determine whether increased risk-taking is a factor in substance use, it may be necessary to use both monetary risk-taking tasks and complementary assessments of non-monetary-based risk-taking measures.
BACKGROUND: Though substance use is often associated with elevated risk-taking in real-world scenarios, many risk-taking tasks in experimental psychology using financial gambles fail to find significant differences between individuals with substance use disorders and healthy controls. We assessed whether participants using marijuana would show a greater propensity for risk-taking in distinct domains including, but not limited to, financial risk-taking. METHODS: In the current study, we assessed risk-taking in young adult (age 18-25) regular marijuana users and in non-using control participants using a domain-specific risk-taking self-report scale (DOSPERT) encompassing five domains of risk-taking (social, financial, recreational, health/safety, and ethical). We also measured behavioral risk-taking using a laboratory monetary risk-taking task. RESULTS:Marijuana users and controls reported significant differences on the social, health/safety, and ethical risk-taking scales, but no differences in the propensity to take recreational or financial risks. Complementing the self-report finding, there were no differences between marijuana users and controls in their performance on the laboratory risk-taking task. CONCLUSIONS: These findings suggest that financial risk-taking may be less sensitive than other domains of risk-taking in assessing differences in risky behavior between those who use marijuana and those who do not. In order to more consistently determine whether increased risk-taking is a factor in substance use, it may be necessary to use both monetary risk-taking tasks and complementary assessments of non-monetary-based risk-taking measures.
Authors: C W Lejuez; Jennifer P Read; Christopher W Kahler; Jerry B Richards; Susan E Ramsey; Gregory L Stuart; David R Strong; Richard A Brown Journal: J Exp Psychol Appl Date: 2002-06
Authors: Harrison G Pope; Amanda J Gruber; James I Hudson; Geoffrey Cohane; Marilyn A Huestis; Deborah Yurgelun-Todd Journal: Drug Alcohol Depend Date: 2003-04-01 Impact factor: 4.492
Authors: Diana H Fishbein; Diana L Eldreth; Christopher Hyde; John A Matochik; Edythe D London; Carlo Contoreggi; Varughese Kurian; Alane S Kimes; Andrew Breeden; Steven Grant Journal: Brain Res Cogn Brain Res Date: 2005-04
Authors: Mason M Silveira; Jonathon C Arnold; Steven R Laviolette; Cecilia J Hillard; Marta Celorrio; María S Aymerich; Wendy K Adams Journal: Neurosci Biobehav Rev Date: 2016-09-14 Impact factor: 8.989
Authors: Julia W Felton; Anahi Collado; Julia M Shadur; Carl W Lejuez; Laura MacPherson Journal: Exp Clin Psychopharmacol Date: 2015-08 Impact factor: 3.157
Authors: Julio A Yanes; Michael C Riedel; Kimberly L Ray; Anna E Kirkland; Ryan T Bird; Emily R Boeving; Meredith A Reid; Raul Gonzalez; Jennifer L Robinson; Angela R Laird; Matthew T Sutherland Journal: J Psychopharmacol Date: 2018-01-17 Impact factor: 4.153
Authors: David R Raymond; Adrian Paneto; Karmen K Yoder; Brian F O'Donnell; Joshua W Brown; William P Hetrick; Sharlene D Newman Journal: Front Psychiatry Date: 2020-11-27 Impact factor: 4.157